Blogs
The challenge The sponsor asked us to develop and validate an electrochemiluminescence (ECL) ligand binding assay (LBA) to detect anti-drug antibodies (ADA) in human serum to support clinical studies. The therapeutic is a bispecific conjugated fusion protein with two functional domains, FD1 and FD2. Furthermore, FD1 has…
Posters & Papers
This case study describes the development and validation of an ELISA method to quantify total antibody (tAb) from PYX-201, an investigational antibody-drug conjugate (ADC) developed by Pyxis Oncology. The assay was validated in rat and monkey plasma and used to support preclinical studies and an IND filing. The method…
Posters & Papers
This case study describes the development and validation of an ELISA method to quantify total antibody (tAb) from PYX-201, an investigational antibody-drug conjugate (ADC) developed by Pyxis Oncology. The assay was validated in rat and monkey plasma and used to support preclinical studies and an IND filing. The method…
Posters & Papers
This article provides updated recommendations for the bioanalysis of antibody-drug conjugates (ADCs), reflecting more than a decade of advances in the field. Developed by the AAPS ADC Working Group, it addresses key considerations for quantifying total antibody, conjugated ADC, free payload, and drug-to-antibody ratio (DAR), as well as immunogenicity,…
Posters & Papers
This article provides harmonized recommendations for the validation and reporting of neutralizing antibody (NAb) assays, addressing challenges associated with both cell-based and non-cell-based formats. Developed by experts from industry and the FDA through the American Association of Pharmaceutical Scientists’ Therapeutic Product Immunogenicity Community, the recommendations cover key assay performance…
Posters & Papers
Bispecific protein therapeutics present unique challenges for pharmacokinetic (PK) characterization because multiple functional domains must be evaluated, along with potential biotransformation and interference from anti-therapeutic antibodies. This review presents case studies and a regulatory perspective on developing PK assay strategies for bispecific molecules, emphasizing the need to consider each…
Blogs
As drug development programs continue to expand into more complex therapeutic modalities and patient-centric clinical trial designs, bioanalytical laboratories are under increasing pressure to generate high-quality data from smaller, less invasive samples. Volumetric absorptive microsampling (VAMS) has emerged as a promising solution, offering a practical alternative to traditional blood…
Videos
Full laboratory tour of the KCAS Bio location in Kansas City, KS USA. Interested in speaking with one of our experts? Fill out the form below to connect with a KCAS Bio scientist.
Videos
Full laboratory tour of the KCAS Bio location in Kansas City, KS USA. Interested in speaking with one of our experts? Fill out the form below to connect with a KCAS Bio scientist.
Blogs
What are functional assays? Understanding the interactions between drugs and biological systems is critical for the success of a new drug. One key tool in this process is functional assays. Functional assays in drug development are customized assays that evaluate the impact of drugs on the functionality of cells.
Blogs
In today’s fast-moving drug development landscape, bioanalytical continuity and end-to-end support aren’t just conveniences, they’re competitive advantages. Sponsors navigating complex modalities like gene therapies, ADCs, oligonucleotides, and biologics need a partner who can keep pace with aggressive timelines, shifting priorities, and evolving regulatory expectations. Why Continuity Matters in…
webinars
Biomarkers can move a program forward fast. Or slow it down with rework. Biomarkers shape decisions from discovery through late-stage clinical trials. But the wrong assay plan can waste time, budget and samples. In this KCAS Bio roundtable, we share practical ways to align context of use,…